Objective: We sought to understand better the disease mechanism of GPP to allow improved targeted therapies. Methods: We performed a gene expression study on formalinfixed paraffin-embedded GPP (n 5 28) and PV (n 5 12) lesional biopsies and healthy control (n 5 20) skin. Differential gene expression was analyzed using gene ontology and enrichment analysis. Gene expression was validated with quantitative RT-PCR and immunohistochemistry, and a potential disease mechanism was investigated using primary human cell culture. Results: Compared with healthy skin, GPP lesions yielded 479 and PV 854 differentially expressed genes, respectively, with 184 upregulated in both diseases. We detected significant contributions of IL-17A, TNF, IL-1, IL-36, and interferons in both diseases; although GPP lesions furnished higher IL-1 and IL-36 and lower IL-17A and IFN-g mRNA expression than PV lesions did. We detected prominent IL-36 expression by keratinocytes proximal to neutrophilic pustules, and we show that both neutrophils and neutrophil proteases activate IL-36. Suggesting another mechanism regulating IL-36 activity, the protease inhibitors serpin A1 and A3, which inhibit elastase and cathepsin G, respectively, were upregulated in both diseases and inhibited activation of IL-36. Conclusions: Our data indicate sustained activation of IL-1 and IL-36 in GPP, inducing neutrophil chemokine expression, infiltration, and pustule formation, suggesting that the IL-1/ IL-36 inflammatory axis is a potent driver of disease pathology in GPP. (J Allergy Clin Immunol 2017;140:109-20.)
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Generalized pustular psoriasis (GPP) (Online Mendelian Inheritance in Man [OMIM] database no. 614204) is a rare, debilitating, and life-threatening disease, characterized by episodic infiltration of neutrophils into the skin, pustule development, generalized erythema, and desquamation. The acute onset of GPP is frequently accompanied by chills, highgrade fever, fatigue, and neutrophilia, which can be potentially life-threatening and require hospitalization. 1 Cases of GPP can occur either as a distinct entity or preceded by, concurrent with, or followed by chronic plaque psoriasis (psoriasis vulgaris [PV]; OMIM no. 177900), which has complicated the study of the disease. GPP is often classified as a variant of PV, yet striking clinical, histologic, and genetic differences suggest that the 2 diseases have distinct pathogenic mechanisms. [1] [2] [3] [4] [5] Many treatments for PV such as acitretin, cyclosporine A, and anti-TNF biologics are in common use for GPP but typically do not completely control the disease. 6 This shortfall in the efficacy of these treatments likely stems from an incomplete overlap of the pathobiology of the 2 diseases. Resistance to existing treatments and disease recurrence are common with GPP, thus there is a critical need to understand better the disease mechanism to develop new effective treatments.
To investigate the pathogenic mechanisms driving GPP, we harnessed a recently developed technique to perform transcriptional profiling on archived formalin-fixed paraffinembedded (FFPE) biopsies 7 of GPP skin to assess the transcriptome of GPP lesions, detect differentially expressed genes, and identify which inflammatory pathways were activated with a view to the development of new therapeutic interventions tailored to GPP. Herein we report that an IL-36-chemokine-neutrophil axis appears to be central to the pathogenesis of GPP, with a greater utilization of innate immune mechanisms, preferential expression of IL-36 cytokines, keratinocyte (KC) expression of neutrophil chemokines, IL-36 activation by neutrophil proteases, and induction of inflammatory keratinocyte responses. Our data provide a rational basis for targeted anticytokine biologic therapy for GPP.
METHODS

Subject recruitment
Archived FFPE tissue was identified by search in our pathology database. Cases with diagnosis of pustular psoriasis were identified, and diagnosis was verified by chart review. Healthy controls and patients with chronic plaque psoriasis were identified in our clinic and biopsy was obtained for formalin fixation and paraffin embedding prior to processing and analyses. Healthy volunteers were recruited for blood draws for neutrophil isolation after providing written informed consent. All protocols were approved by the institutional review board of the University of Michigan, Ann Arbor, and the study was carried out in accordance with the Declaration of Helsinki principles.
Microarray analysis
RNA extraction was performed with an E.Z.N.A. FFPE RNA isolation kit (Omega Bio-tek, Norcross, Ga) using the xylene-based extraction method as specified by manufacturer and 5 20-mm thick FFPE sections of biopsy. RNA was eluted into water and stored at 2808C until analyzed. Affymetrix Human Gene ST 2.1 microarrays (Affymetrix, Santa Clara, Calif) were processed at the University of Michigan Microarray Core Facility according to the manufacturer's protocol. Raw microarray data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus ([GEO], http://www.ncbi.nlm.nih.gov/geo) and are accessible through GEO series accession number GSE79704. The raw microarray data (CEL files) were processed in the publicly available software R (www.r-project.org) using a modified version of the ''affy'' package and Human Entrez Gene custom CDF annotation version 19 8 (http://brainarray.mbni.med.umich.edu/ Brainarray/Database/CustomCDF/genomic_curated_CDF.asp) using the Robust Multichip Average method. 9 Posthybridization quality control checks were performed using RNA degradation score, relative log expression, and normalized unscaled standard errors. Data were batch-and age-corrected using an implementation of ComBat version 3 10 within the GenePattern pipeline (http://www.GenePattern.org). To remove background, we calculated the median values of all probe sets and removed those probes with expression values below the lowest median value 1 1 SD using a custom Perl script. This yielded 25,561 probe sets on which subsequent analyses were based. Statistical analyses were performed using Significance Analysis of Microarrays method implemented in the MultiExperiment Viewer application. 11 Hierarchical clustering and principal components analysis were performed on the adjusted expression data using R and gene list comparisons done in Genomatix (www.genomatix.de).
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was performed as described 12 with the following modifications. The top 250 genes expressed by KC, CD4
1
T cells, CD8
1 T cells, monocytes, neutrophils, and dendritic cells (DCs) as listed previously 13 or cytokine-treated KC 14 were matched against a ranked list of differentially expressed genes (DEGs) in averaged GPP and PV samples. The rank order of matching genes was used to construct a cumulative curve. Effect size was estimated by calculating the area under the curve and normalizing to the maximum possible effect size for each 250-member gene set. Statistical significance was determined by using a phenotype-based permutation test, which preserves the complex coexpression relationships of gene expression data. 12 Gene ontology (GO) analysis was performed using the GO_ImmuneSystemProcesses ontology set using ClueGo version 2.2.4 in the Cytoscape version 3.2.1 environment. 15 A kappa score threshold of 0.4 was used to build networks and a 2-sided hypergeometric test with Bonferroni step-down correction to determine statistical significance.
Quantitative PCR
Real-time RT-PCR was performed after reverse transcribing RNA (High Capacity cDNA Transcription kit; Applied Biosystems, Foster City, Calif) quantifying transcripts using a 7900HT Fast Real-Time PCR system (Applied Biosystems) using TaqMan primer sets purchased from Applied Biosystems. All values were normalized to the expression of the housekeeping gene RPLP0. Statistical significance among healthy, PV, and GPP samples was determined using a Kruskal-Wallace test with Dunn multiple comparison test in GraphPad Prism version 6 (GraphPad, San Diego, Calif).
Immunohistochemistry
Immunohistochemistry was performed on FFPE human skin biopsies sectioned at 5 mm, and then immunohistochemically stained after antigen retrieval using polyclonal goat anti-IL-36a (1 mg/mL, AF1078; R&D Systems, Minneapolis, Minn), IL-36g (2.5 mg/mL, rat, Y-12; Santa Cruz Biotechnology, Santa Cruz, Calif), polyclonal goat anti-CXCL8 (5 mg/mL, AF2008; R&D Systems), polyclonal rabbit anticathepsin G (5 mg/mL, NBP233498; Novus Biologicals, Littleton, Colo), neutrophil elastase (1 mg/mL, mouse, NP57; Dako, Agilent Technologies, Santa Clara, Calif), proteinase 3 (1 mg/mL, EPR6277; LifeSpan Biosciences, Seattle, Wash), and matched isotype control antibodies. Immunoreactivity was visualized with 3,39-diaminobenzidine and counterstained with hematoxylin.
IL-36 activation
Neutrophils were prepared from heparinized peripheral blood from healthy volunteers using ficoll and 3% dextran as described. 16 Neutrophil extracellular traps (NETs) were generated on poly-L-lysine-coated (Sigma-Aldrich, St Louis, Mo) 12-well cell culture plates (Costar; Corning Inc, Corning, NY) using 1 million neutrophils stimulated with 20 nmol/L phorbol 12-myristate 13-acetate for 3 hours at 378C. NET formation was confirmed by fluorescent microscopy with 49-6-diamidino-2-phenylindole, dihydrochloride staining of DNA. After extensive washing with PBS, 500 mL of 0.5 mg/mL full-length (FL)-IL-36a or FL-IL-36g in PBS were incubated with NETs for 1 hour at 378C. After which, the processed IL-36 solutions were added to confluent cultures of primary human KC for 24 hours to determine IL-36 activity. Truncated IL-36a (aa 6-158) and IL-36g (aa 18-169) (R&D Systems) were used at 100 ng/mL as positive controls. IL-36 activity was determined from its induction of CXCL1 and CXCL8 mRNA transcripts.
IL-36 activity assays were performed using 100 ng/mL FL IL-36a or FL IL-36g (R&D Systems) in unsupplemented medium 154CF (Invitrogen, Thermo Fisher Scientific, Waltham, Mass), treated with 10 mU neutrophil elastase (Enzo Life Sciences, Farmingdale, NY) or 1 mU cathepsin G (Enzo), for 30 minutes at 378C, then the reactions were quenched with cathepsin G inhibitor I (50 mmol/L; EMD Millipore, Darmstadt, Germany), trypsin inhibitor (15 mg/mL, inhibiting elastase activity; Sigma-Aldrich), serpin A1 (1 mg/mL; Enzo), or serpin A3 (1 mg/mL; Enzo). The mixtures were then transferred onto confluent cultures of primary human KC for 24 hours. IL-36 activity was determined as described above.
RESULTS
Plaque and pustular psoriasis are pathogenically distinct
To assess the pathophysiological differences between GPP and PV, we analyzed archived FFPE biopsies of confirmed GPP (n 5 28) and PV (n 5 12) cases and healthy control (n 5 20) skin using Affymetrix Human Gene ST 2.1 microarrays. After batch correction, unsupervised principal component analysis (Fig 1, A) of the GPP, PV, and healthy control samples showed complete separation of the GPP and PV samples from the healthy samples, but there was substantial overlap between the plaque and pustular samples. Unsupervised clustering of transcripts confirmed separation of healthy control and disease samples as well as overlap of GPP and PV transcriptomes (Fig 1, B) . Interestingly, chart review revealed that 7 of 28 GPP cases had concurrent PV, and when analyzed by unsupervised clustering analysis, these 7 cases clustered with the GPP-only samples (Fig 1, B) . Using significance analysis for microarrays, gene expression in GPP and PV lesions were compared with healthy skin, finding 479 DEGs in GPP and 854 DEGs in PV with at least a 2-fold change in expression (false discovery rate, P < .05) with 184 of these transcripts differentially expressed in both diseases (Fig 1, C; and see Table E1 in this article's Online Repository at www. jacionline.org).
Of the 479 DEGs in GPP versus healthy skin, 235 were upregulated and 292 downregulated. The upregulated transcripts mapped to 13 GO Immune System Process terms, with processes related to granulocyte chemotaxis mapping to the vast majority of transcripts (upper panel, Fig 2; and see Table E2 in this article's Online Repository at www.jacionline.org). In contrast, of the 854 DEGs in PV, 169 mapped to 9 GO terms, which included several categories related to the adaptive immune response (lower panel, Fig 2; and see Table E2 ).
Pustular psoriasis lesions have heightened IL-1/36 cytokine activity
DEGs in PV and GPP were interrogated using GSEA using gene sets composed of the 250 most abundantly expressed genes in KCs, CD4
1 T cells, CD8 1 T cells, monocytes, neutrophils, and DCs. 13 This revealed that a greater abundance of genes expressed by neutrophils and monocytes were detected in GPP compared with PV biopsies (Fig 3, A and B) . We extended this approach by using gene sets generated from KC cultures treated with a panel of recombinant cytokines to discern cytokine activity in the biopsies. We found evidence of IL-17A, IL-1b, IL-36a, IL36g, IL-22, TNF-a, and IFN-g activity in the tissues, with much of this cytokine activity more prominent in pustular lesions than plaque biopsies (Fig 3, C and D) .
To confirm the increased cytokine activity in GPP skin biopsies, we performed quantitative RT-PCR and found that although we could confirm increased expression of IL-1b, IL-1RA, IL-36a, IL-36b, IL-36g, and IL-36RA in plaque psoriasis skin, we found a significantly greater abundance of transcripts for IL-1b, IL-36a, and IL-36g in GPP versus PV lesions, with no significant changes in the expression levels of the respective receptor antagonists (Fig 4, A) . Conversely, and suggesting a departure from typical T H 1/T H 17 pathophysiology, we found that transcripts for IL-17A, IL-22, IL-23p19, IFN-g, IL-18, and myxovirus resistance 1 (MX1, an interferon response gene) were all significantly more abundant in plaques than in pustular lesions (Fig 4, B) . The elevated IL-36a and IL-36g expression in GPP was confirmed at the level of protein expression by immunohistochemistry, with an increased intensity of IL-36a and IL-36g expression, particularly by the KC surrounding the neutrophilic pustule, but not the neutrophils themselves (Fig 5) .
The neutrophilic environment of GPP lesions activates IL-36a and IL-36g
GPP is characterized by periodic neutrophil infiltration into the skin and development of pustules. In concordance with this we observed strongly enhanced expression of the neutrophil chemokines CXCL1, CXCL2, and CXCL8 (IL-8) in GPP, likely the factors driving the neutrophilic skin infiltration. Compared with plaque lesions, we found 15-, 5.8-, and 20-fold more transcripts for CXCL1, CXCL2, and CXCL8 in GPP lesions, respectively (Fig 6, A-C) . The enhanced expression of CXCL8 was particularly striking also at the level of protein expression (Fig 6, D and E) . Given that we witnessed significantly more IL-36 expression in GPP compared with PV lesions and that neutrophils have been suggested to be a source of enzymes that are capable of processing IL-36 isoforms, 17, 18 we assessed the expression of neutrophilic proteases in GPP, as well as the presence of networks of extracellular DNA suggestive of NETs, structures resulting from the programmed death of neutrophils (netosis), which expose the neutrophil proteases elastase, cathepsin G, and proteinase 3 to the extracellular milieu. NETs were detected in both PV and GPP skin (Fig 6, F) and immunohistochemistry confirmed the expression of cathepsin G, elastase, and proteinase 3 by neutrophils in GPP skin (Fig 6, G-I) .
Given the close juxtaposition of heightened levels of IL-36 cytokines and the proteases implicated in their proteolytic activation, we then asked whether neutrophil NETs were capable of activating IL-36a and IL-36g in vitro. FL-IL-36a and FL-IL-36g were treated with NETs generated from phorbol 12-myristate 13-acetate-activated neutrophils for 1 hour then exposed to cultures of primary human KCs to assay their activity with respect to the induction of KC inflammatory responses. Exposure to NETs significantly increased the ability of FL-IL36g to induce CXCL1 and CXCL8 expression by KCs more than 3-fold compared with untreated FL-IL-36g (Fig 7, A and  C) , suggesting that enzyme activity within the NETs caused FL-IL-36g activation. Next we approached the IL-36 activation question using purified neutrophil elastase and cathepsin G to examine their influence on the activity of FL-IL-36a and FL-IL-36g. Treatment of FL-IL-36a (1 mg/mL) with 10 mU neutrophil elastase before addition to cultures of primary KCs lead to enhanced KC production of CXCL1, CXCL2, IL-8, and CCL20 transcripts (Fig 7, E-H) . However, treatment of FL-IL-36a with cathepsin G did not increase the cytokine's activity. On the other hand, no increase in FL-IL-36g activity was seen with elastase treatment, but incubation of FL-IL-36g A, Principal component analysis of the GPP, PV, and NN samples showed segregation of the GPP and PV samples from the healthy samples, with some overlap between the plaque and pustular samples. NN, PV, PV1GPP, and GPP-only phenotypes are indicated by green, red, purple, and blue spheres, respectively. B, A heat map generated from unsupervised clustering of differentially expressed transcripts among GPP, PV, and NN skin shows heterogeneity of healthy and disease samples. For clarity, the 79 transcripts with 0.25 > fold change (FC) > 4.0, and false discovery rate P < .05 were selected. Blue indicates low expression levels whereas red indicates high expression levels. The green, red, purple, and blue bars above the heat map indicate NN, PV, PV1GPP, and GPP-only skin samples, respectively. C, Volcano plots of gene expression showing roughly equal numbers of upregulated and downregulated genes in each disease although many of the downregulated transcripts in PV did not reach statistical significance. Yellow indicates transcripts with 0.5 > FC > 2, red denotes false discovery rate P < .05, and green labels transcripts satisfying both criteria (upper panels). Despite overlap of differentially expressed genes between PV and GPP skin lesions, each disease had a set of uniquely expressed transcripts (lower panel).
with 1 mU cathepsin G led to a significant increase in its ability to induce chemokine transcript production by KCs (Fig 7, I-L) .
Physiologic protease inhibitors serpin A1 and A3 regulate IL-36 activation
Serpin A1 and A3 are extracellular protease inhibitors with activity against neutrophil elastase and cathepsin G, respectively. 19 Here we found that the induction of FL-IL-36a activity was prevented by addition of serpin A1 (Fig 7, E-H) , and FL-IL-36g activity was prevented by treatment with the specific cathepsin G inhibitor serpin A3 (Fig 7, I-L) . Suggestive of attempts, albeit insufficient, to regulate IL-36 activity in skin, both of these protease inhibitors were found to be upregulated in our microarray dataset: serpin A1 was 1.86-fold (q 5 0.0048) and 1.78-fold (q < 0.001) upregulated in PV and GPP lesions, respectively, compared with healthy skin; whereas serpin A3 expression was increased 1.94-fold (q 5 0.020) and 2.2-fold (q 5 0.035) in PV and GPP lesions, respectively.
DISCUSSION
The adaptive immune system, particularly CD41 and CD81 T cells, has a critical, if not causal, role in the pathogenesis of PV and as such, agents specifically targeting elements of adaptive immunity have had great success in treating plaque psoriasis. 20, 21 These therapies are generally less effective for GPP, 6 suggesting a divergent pathogenic mechanism in the pustular disease. Using archived FFPE skin biopsy material, microarrays, and a bioinformatics approach, we have revealed that although the transcriptome of GPP overlaps with PV (Fig 1) , the pustular disease has a much more pronounced utilization of the innate immune system than PV does (Fig 2; and see Table E2 ). Our data suggest that GPP is a disease primarily involving the activities of KCs, neutrophils, and monocytes (Fig 3, A) , with inflammatory processes mainly driven by IL-36, IL-1, or TNF-a/IL-17A (Fig 3, B) . Moreover, the increased expression (Figs 4 and 5) , processing, and activity (Fig 7) of IL-36 cytokines might be a central mechanism that promotes neutrophil accumulation in the epidermis. The importance of IL-36 in pustular skin disease was recently highlighted when missense mutations in IL36RN, which affect the structure and function of the IL-36 receptor antagonist (IL-36RA), were found to be associated with GPP. 3, 22 Loss of IL-36RA function leads to unrestrained IL-36 activity, as evidenced by induction of IL-1b, IL-6, and IL-8 production, and neutrophil infiltration. GPP can present alone, preceded by, concurrent with, or followed by PV.
1 Mutations in IL36RN have been shown to account for 46% to 82% of cases of GPP without associated PV. 5, 23 The proportion of IL36RN mutant carriage is much lower (10% to 17%) in cases of GPP associated with PV, 2 supporting the notion of divergent pathogenic mechanisms in the 2 diseases. A recent meta-analysis of 233 GPP cases revealed that carriage of 1 or 2 IL36RN mutant alleles conferred a more severe clinical phenotype with an earlier age of onset and Table E2 . MHC, Major histocompatibility complex; TAP, transporter associated with antigen processing.
FIG 3.
Neutrophil and monocyte transcripts show greater enrichment in pustular psoriasis (GPP) lesions than plaque psoriasis (PV), whereas robust cytokine gene induction is evident in both diseases. Microarray datasets for KC, CD4
1 T cells, CD8 1 T cells, monocytes, neutrophils, and DCs were compiled and used to generate signature gene lists. 13 DEGs in PV versus NN and GPP versus NN comparisons were ordered by fold-change and the rank position of each of the cell signature genes was noted and cumulative overlap between the sets was plotted (red/blue line), showing a greater upregulation of neutrophil-specific genes in GPP than in PV lesions. Gray areas indicate space generated by 1000 random permutations of NN, PV, and GPP datasets from which statistical significance is derived (A). Data from each of the cell signature comparisons is summarized, red bars indicate PV, blue bars indicate GPP, and statistical significance indicated by *P < .05 permutation test (B). Likewise gene signatures for cytokine activity on KCs were generated and used to discern cytokine activity within the PV and GPP samples, showing prominent and significant presence of genes induced by TNF-a1IL17A in PV and GPP lesions, contrasted by the lack of enrichment in genes induced by IL-19 (C, D) . AUC, Area under the curve.
increased risk of systemic inflammation than noncarriage does. 2 A gene-dosage effect was also apparent in that homozygous carriers had an earlier age of onset than heterozygotes did. In addition, mutations in AP1S3 24 and CARD14 25 affecting the structure and function of the AP-1 complex subunit s1C and the nuclear factor-kB activator CARD14, respectively, have also been associated with GPP, giving further insight into the mechanisms that may underlie this disease.
The 3 isoforms of IL-36-IL-36a, IL-36b, and IL-36g-form a trio of proinflammatory IL-1 family cytokines that we 26 and IL1RN and IL36RN (A) . Suggesting a departure from typical TH1/TH17 pathophysiology, IL23A, IL17A, IFNG, CXCL9, CXCL10, and MX1 transcript expression was found to be significantly lower in GPP compared with PV lesions (B). Statistical significance indicated: *P < .05, **P < .01, ***P < .001, ****P < .0001. Kruskal-Wallace test with Dunn multiple comparison test. others 27, 28 have shown are overexpressed in plaque psoriasis skin, where they may drive KC inflammatory responses, 26 synergize with other proinflammatory cytokines, 26, 29 and promote DC activation. 30, 31 The effects of IL-36 on skin have been modeled in mice. 26, 27 Transgenic expression of IL-36a in murine epidermis lead to epidermal thickening, hyperkeratosis, mixed inflammatory cell infiltrate, and elevated chemokine expression (CCL2, CXCL6, CCL7, and CXCL2). 27 Backcrossing to an Il-36rn-deficient mouse resulted in more severe skin lesions, reflecting the effect of nonsense IL-36RN mutations in GPP. This phenotype was partly reversed by the use of an anti-Gr1 neutrophil-depleting antibody or TNF-neutralizing antibodies, suggesting roles for both neutrophils and TNF in IL-36a-induced skin hyperplasia. IL-36a injected subcutaneously into mice induces acanthosis and a striking infiltration of granulocytes (CD11b 1 ) concomitant with chemokine and growth factor induction. 30 IL-36 family expression is also elevated in the skin of psoriasiform KC-Tie2 mice 26 and during imiquimod-induced skin inflammation. 26, 32 One of the early features of imiquimod-treated mouse skin is neutrophil infiltration, and the inflammatory phenotype is ablated in IL-36 receptor-deficient mice, 32 further implicating a neutrophil/IL-36 axis as a central driver in the development of skin inflammation in GPP.
Like their IL-1 family counterparts-IL-1b, IL-18, and IL-33 [33] [34] [35] -the IL-36 cytokines require N-terminal peptide cleavage for activity, 36 and it was recently demonstrated that IL-36 activation could be carried out by the neutrophil serine proteases elastase and cathepsin G. 17 Here we show that neutrophils activated to form NETs have the ability to activate FL-IL-36g (Fig 7, A-D) and of the 3 proteases prominently expressed in neutrophilic pustules (Fig 6, G-H) , elastase could activate IL-36a and cathepsin G was found to activate IL-36g, increasing their ability to induce KCs to produce neutrophil chemokines (Fig 7, E-L) . Interestingly, we detected an upregulation of 2 endogenous protease inhibitors, serpins A1 and A3, in both PV and GPP (Fig 7, E-L ) that appear to be labile to induction by inflammatory cytokines (data not shown), suggesting a counterregulatory mechanism to control IL-36 activity. However, the serpin mechanism of action is one of suicide inhibition and a 1:1 serpin-protease stoichiometry is required, 19 thus the approximate 2-fold upregulation of serpins A1 and A3 we detected in lesional skin is unlikely to counter the formidable protease expression afforded by the neutrophilic infiltrate (Fig 6) . This imbalance may suggest an as yet unexplored therapeutic angle in pustular diseases.
We have shown that GPP uses pathways both overlapping and separate from PV, and that because of their efficacy in moderatesevere PV, a number of therapies specifically targeting cytokines are in use for GPP. Several reports describe the use of the anakinra, an IL-1 receptor antagonist, to treat GPP. [37] [38] [39] Anakinra appears to induce a rapid normalization of systemic inflammatory symptoms followed by improvement of the pustular skin eruption. The responses to IL-1 receptor inhibition in the skin tend to be incomplete, however, with erythema and hyperkeratosis remaining in some cases, which suggests that IL-1 is not playing a central role in GPP and instead acts in a positive feedback loop inducing and being induced by IL-36. 26 The relevance of using IL-1 receptor antagonism to tackle a disease that may be primarily driven by deviations in IL-36 signaling, particularly when IL36RN mutations are present, has recently been questioned. 40 TNF-a is a central mediator in chronic plaque psoriasis as evidenced by the effectiveness of therapies that block TNF-a activity. Of the 3 TNF blockers in use for PV, infliximab has most commonly been used for GPP, 41, 42 and as such has become The neutrophil chemokines CXCL1, CXCL2, and CXCL8 are more strongly expressed in GPP than in PV lesions. Using quantitative RT-PCR, we detected significantly higher expression of CXCL1, CXCL2, and IL8 transcripts in GPP (n 5 20) compared with plaque psoriasis (n 5 12) or healthy control skin (n 5 12) (A-C). CXCL8 immunoreactivity was barely evident in PV (D) but very strong in and around neutrophilic pustules in GPP biopsies (E). NET formation was prominent in GPP lesions as visualized with 49-6-diamidino-2-phenylindole, dihydrochloride (DAPI) (F) as was the expression of the neutrophil proteases cathepsin G, elastase, and proteinase 3 in GPP (G, H, I) but not healthy control skin (J, K, L). Representative images of at least 6 GPP, PV, NN donors used (see Fig E1) . Scale bars 5 200 mm (D, E, G-L) and 10 mm (F). Statistical significance indicated: *P < .05, **P < .01, ****P < .0001. KruskalWallace test with Dunn multiple comparison test.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 1 one of the recommended treatment options for severe acute GPP despite the lack of adequate clinical trials. 6 Infliximab has been reported to have a rapid effect, with systemic inflammation and skin pustules starting to recede in as little as 2 days from the first infusion. In this context, the efficacy of infliximab likely stems from the rapid availability of the drug following infusion, and its inhibition of the synergy between TNF and multiple inflammatory cytokines including IL-36, IL-17A, and IL-1b. 26, 29, 43, 44 We detected increased IL-17A activity in GPP lesions using GSEA of microarray data (Fig 3) despite not being able to detect a significant increase in IL-17A transcripts by quantitative RT-PCR (Fig 4) ; this discordance may be the result of the lack of sensitivity of the PCR assay for IL-17A in FFPE samples, contrasting with the ability of GSEA to detect the downstream effects of cytokines on transcriptional networks, or possibly similarities in IL-1/17/ 36-induced gene sets driving a perceived IL-17A signature in the data. Notwithstanding, biologics targeting IL-17A signaling have been used with success for GPP. An initial case report detailed the rapid improvement of both systemic symptoms and the skin disease of 1 GPP patient with secukinumab, 45 followed by a clinical trial that provided encouraging, but because of its design not conclusive, data from 10 of 11 GPP patients on secukinumab. 46 Likewise brodalumab, a biologic targeting IL-17RA, was shown to induce clinical improvement in 11 of 12 GPP patients. 47 The above-mentioned therapies have largely been tested empirically for GPP, but now our data (Figs 3 and 4) provide evidence for the selection of these treatments as we demonstrate that responses to IL-1, IL-17A, and TNF-a are heightened in GPP, with the IL-1 and IL-36 families of cytokines being the most robust. Our data provide a rational basis for the development of therapies specifically targeting these pathways, particularly the IL-36 system in GPP. 48, 49 We thank the research subjects who participated in this study. We also thank Dr Stefan W. Stoll for kindly providing primary keratinocyte cultures. We acknowledge Drs Celine Berthier, Viji Nair (Internal Medicine, University of Michigan, supported by National Institutes of Health [NIH] award , I-L) activated FL-IL-36a and FL-IL-36g, respectively, which was inhibited by the addition of specific inhibitors of elastase (serpin A1) or cathepsin G (serpin A3). Statistical significance determined with Student t test and indicated: *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., Not significant.
